Verneuil Vanina De Sells 2,347 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 2,347 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $9.47, for a total value of $22,226.09. Following the sale, the executive vice president now owns 61,370 shares of the company’s stock, valued at approximately $581,173.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Verneuil Vanina De also recently made the following trade(s):

• On Friday, November 1st, Verneuil Vanina De sold 1,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.20, for a total value of $10,101.60.

Vir Biotechnology Stock Up 2.9 %

VIR stock traded up $0.27 during midday trading on Tuesday, reaching $9.64. 1,110,639 shares of the company’s stock traded hands, compared to its average volume of 1,024,860. The firm’s fifty day moving average price is $7.77 and its 200-day moving average price is $8.88. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -2.46 and a beta of 0.46. Vir Biotechnology, Inc. has a 52 week low of $7.12 and a 52 week high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $5.54 million. During the same period last year, the company earned ($1.22) earnings per share. The business’s revenue for the quarter was down 9.8% compared to the same quarter last year. Analysts forecast that Vir Biotechnology, Inc. will post -3.26 earnings per share for the current year.

Institutional Trading of Vir Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in VIR. Innealta Capital LLC bought a new position in Vir Biotechnology in the 2nd quarter valued at $32,000. Blue Trust Inc. grew its position in Vir Biotechnology by 143.5% during the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares during the period. nVerses Capital LLC bought a new position in Vir Biotechnology during the third quarter valued at about $56,000. Magnetar Financial LLC purchased a new stake in Vir Biotechnology during the second quarter worth about $95,000. Finally, Headlands Technologies LLC bought a new stake in Vir Biotechnology in the first quarter worth about $119,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on VIR shares. HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Monday. Barclays cut their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research note on Friday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $36.40.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).